The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-19-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
The patent is stated not to expire until 2010 and this will put a 30 hold at the FDA to grant approval. This one should prove interesting to follow and see where the infringement occurs. BD LONDON -(Dow Jones)- Sanofi-Aventis SA (SNY) has launched a legal action against Canadian generic drugmaker...